Antengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022

Phase 3ATG-022Positive

AI Analysis

Summary

Antengene announced the first patient enrollment in the pivotal Phase III CLINCH-3 study of ATG-022. This milestone marks advancement toward potential regulatory submissions for the investigational drug.

Clinical Trial Data

Phase

Phase III

Outcome Details

First patient dosed in pivotal Phase III CLINCH-3 study

Importance:6/10

Sentiment:

0.40

Phase 3Clinical TrialPivotal StudyFirst Patient Dosed

Related Companies

$GBCYD $TRAX

Read the original article

Published by PR Newswire Biotech on September 21, 2026 12:30 AM

Read Original